Valuation: Bicycle Therapeutics plc

Market Cap 236M 214M 198M 179M 337M 22.27B 349M 2.38B 943M 11.9B 886M 868M 37.77B P/E 2026 *
-1.49x
P/E 2027 * -1.43x
Enterprise Value -211M -191M -177M -160M -301M -19.89B -311M -2.12B -842M -10.63B -792M -775M -33.73B EV / Sales 2026 *
-5.55x
EV / Sales 2027 * -23.9x
Free-Float
71.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.32%
1 week-6.65%
Current month-7.92%
1 month-7.16%
3 months-15.33%
6 months-28.90%
Current year-52.40%
1 week 3.26
Extreme 3.26
3.84
1 month 3.26
Extreme 3.26
4.14
Current year 3.26
Extreme 3.26
7.34
1 year 3.26
Extreme 3.26
7.83
3 years 3.26
Extreme 3.26
28.67
5 years 3.26
Extreme 3.26
62.08
10 years 3.26
Extreme 3.26
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Sell

Chief Operating Officer

-356 0.0009%
5/10/26 Sell

Chief Operating Officer

-406 0.0011%
5/10/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-2.32%-6.65%-48.94%-75.42% 236M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.79%-0.62%+29.09%+162.23% 41B
Weighted average by Cap. -0.83%+0.20%+37.18%+162.05%

Financials

2026 *2027 *
Net sales 38.04M 34.47M 31.88M 28.77M 54.21M 3.59B 56.12M 383M 152M 1.92B 143M 140M 6.08B 6.95M 6.3M 5.82M 5.25M 9.9M 655M 10.25M 69.95M 27.74M 350M 26.07M 25.52M 1.11B
Net income -158M -144M -133M -120M -226M -14.94B -234M -1.59B -632M -7.98B -594M -582M -25.33B -174M -157M -146M -131M -248M -16.38B -256M -1.75B -694M -8.75B -652M -638M -27.77B
Net Debt -447M -405M -375M -338M -637M -42.17B -660M -4.5B -1.79B -22.52B -1.68B -1.64B -71.5B -403M -365M -337M -304M -574M -37.95B -594M -4.05B -1.61B -20.27B -1.51B -1.48B -64.36B
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
13/11/26 USD 3.370 -2.32% 604,366
12/11/26 USD 3.450 -6.50% 630,101
11/11/26 USD 3.690 0.00% 171,799
10/11/26 USD 3.690 -2.12% 234,734
09/11/26 USD 3.770 +4.43% 590,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.370USD
Average target price
9.167USD
Spread / Average Target
+172.01%
  1. Stock Market
  2. Stocks
  3. BCYC Stock